A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models

Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.

Authors

Jiansheng Fan¹, Xinlei Zhuang¹, Xiaoyue Yang¹, Yingchun Xu¹, Zhan Zhou¹, Liqiang Pan², Shuqing Chen³

Affiliations

¹ Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
² Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. panliqiang@zju.edu.cn.
³ Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. chenshuqing@zju.edu.cn.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents, Immunological / immunology
Antineoplastic Agents, Immunological / pharmacology*
Cell Line, Tumor
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / immunology
Humans
Immunoconjugates / immunology
Immunoconjugates / pharmacology*
Mice
Neoplasm Proteins / antagonists & inhibitors*
Neoplasm Proteins / immunology
Neoplasms, Experimental / drug therapy*
Neoplasms, Experimental / immunology
Single-Domain Antibodies / immunology
Single-Domain Antibodies / pharmacology*
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
Neoplasm Proteins
Single-Domain Antibodies
EGFR protein, human
ErbB Receptors